Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERTIC strategy with camrelizumab and apatinib after first-line failure in unresectable advanced hepatocellular carcinoma
ChiCTR2600131181Phase 2Not yet recruiting
- Sponsor
- Mengchao Hepatobiliary Hospital of Fujian Medical University
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, Rivoceranib and polyinosine-polycytidylic acid in hepatocellular carcinoma (HCC), sponsored by Mengchao Hepatobiliary Hospital of Fujian Medical University. Primary endpoints: Objective response rate, Overall survival and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibpolyinosine-polycytidylic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600131181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131181.